You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 19, 2024

~ Buy the ZONTIVITY (vorapaxar sulfate) Drug Profile, 2024 PDF Report in the Report Store ~

ZONTIVITY Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


Which patents cover Zontivity, and when can generic versions of Zontivity launch?

Zontivity is a drug marketed by Xspire Pharma and is included in one NDA. There are two patents protecting this drug.

This drug has one hundred and sixty-four patent family members in thirty-seven countries.

The generic ingredient in ZONTIVITY is vorapaxar sulfate. Additional details are available on the vorapaxar sulfate profile page.

DrugPatentWatch® Generic Entry Outlook for Zontivity

Zontivity was eligible for patent challenges on May 8, 2018.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be December 23, 2027. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

< Available with Subscription >

  Try a Trial

Summary for ZONTIVITY
International Patents:164
US Patents:2
Applicants:1
NDAs:1
Raw Ingredient (Bulk) Api Vendors: 47
Clinical Trials: 5
Patent Applications: 7
Drug Prices: Drug price information for ZONTIVITY
What excipients (inactive ingredients) are in ZONTIVITY?ZONTIVITY excipients list
DailyMed Link:ZONTIVITY at DailyMed
Drug patent expirations by year for ZONTIVITY
Drug Prices for ZONTIVITY

See drug prices for ZONTIVITY

DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for ZONTIVITY
Generic Entry Date for ZONTIVITY*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
TABLET;ORAL

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for ZONTIVITY

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Vanderbilt UniversityPhase 4
Vanderbilt University Medical CenterPhase 4
University of FloridaPhase 4

See all ZONTIVITY clinical trials

US Patents and Regulatory Information for ZONTIVITY

ZONTIVITY is protected by two US patents.

Based on analysis by DrugPatentWatch, the earliest date for a generic version of ZONTIVITY is ⤷  Try a Trial.

This potential generic entry date is based on patent ⤷  Try a Trial.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Patents protecting ZONTIVITY

Thrombin receptor antagonists
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial
Patented Use: REDUCTION OF THROMBOTIC CARDIOVASCULAR EVENTS

Thrombin receptor antagonists
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial
Patented Use: REDUCTION OF THROMBOTIC CARDIOVASCULAR EVENTS IN PATIENTS WITH A HISTORY OF MYOCARDIAL INFARCTION (MI) OR WITH PERIPHERAL ARTERIAL DISEASE (PAD)

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Xspire Pharma ZONTIVITY vorapaxar sulfate TABLET;ORAL 204886-001 May 8, 2014 RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial Y Y ⤷  Try a Trial
Xspire Pharma ZONTIVITY vorapaxar sulfate TABLET;ORAL 204886-001 May 8, 2014 RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial Y Y ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

International Patents for ZONTIVITY

See the table below for patents covering ZONTIVITY around the world.

Country Patent Number Title Estimated Expiration
Ecuador SP045368 "ANTAGONISTAS DE LOS RECEPTORES DE TROMBINA" ⤷  Try a Trial
Spain 2357876 ⤷  Try a Trial
South Africa 200605550 Crystalline polymorph of a bisulfate salt of a thrombin receptor antagonist ⤷  Try a Trial
Japan 2010132710 TRICYCLIC THROMBIN RECEPTOR ANTAGONIST ⤷  Try a Trial
Hong Kong 1051183 Thrombin receptor antagonists ⤷  Try a Trial
South Korea 20030008161 트롬빈 수용체 길항제 (Thrombin receptor antagonists) ⤷  Try a Trial
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for ZONTIVITY

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
1495018 300746 Netherlands ⤷  Try a Trial PRODUCT NAME: VORAPAXAR, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT OF SOLVAAT, IN HET BIJZONDER VORAPAXARSULFAAT; REGISTRATION NO/DATE: EU/1/14/976/001-006 20150121
1495018 15C0047 France ⤷  Try a Trial PRODUCT NAME: VORAPAXAR,OU L'UN DE SES SELS OU SOLVATES PHARMACEUTIQUEMENT ACCEPTABLES; REGISTRATION NO/DATE: EU/1/14/976/001-006 20150121
1495018 S1500036 Hungary ⤷  Try a Trial PRODUCT NAME: VORAPAXAR; REGISTRATION NO/DATE: EU/1/14/976 20150119
1495018 PA2015027,C1495018 Lithuania ⤷  Try a Trial PRODUCT NAME: VORAPAKSARAS; REGISTRATION NO/DATE: EU/1/14/976/001 - EU/1/14/976/006 20150119
1495018 CA 2015 00037 Denmark ⤷  Try a Trial PRODUCT NAME: VORAPAXAR, OR A PHARMACEUTICALLY ACCEPTABLE SALT OR SOLVATE THEREOF, INCLUDING VORAPAXARSULPHATE; REG. NO/DATE: EU/1/14/976/001-06 20150119
1495018 34/2015 Austria ⤷  Try a Trial PRODUCT NAME: VORAPAXAR, ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ ODER SOLVAT DAVON; REGISTRATION NO/DATE: EU/1/14/976 20150119
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.